Literature DB >> 15023271

Current Assessment of Yellow Fever and Yellow Fever Vaccine.

Anabelle Lefeuvre1, Philippe Marianneau, Vincent Deubel.   

Abstract

Yellow fever (YF) is a mosquito-borne viral illness that causes hemorrhagic fever in tropical Africa and South America. Although a very safe and efficient vaccine (17D) is available, it is underused. An estimated 200,000 people are still infected annually, and YF remains a major public health concern. This article reviews the recent data on YF epidemiology, virology, and immunity, and analyzes the rare postvaccination adverse effects that have been recently reported. YF vaccine should be included in the expanded program of immunization for children and sustained for people living in or traveling to endemic areas. A surveillance of vaccinated people also should be reinforced. New research programs should be developed to identify molecular markers of YF virus tropism and attenuation, and to understand mechanisms of host responses to virus infection.

Entities:  

Year:  2004        PMID: 15023271     DOI: 10.1007/s11908-996-0005-9

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  72 in total

1.  High fidelity of yellow fever virus RNA polymerase.

Authors:  Konstantin V Pugachev; Farshad Guirakhoo; Simeon W Ocran; Fred Mitchell; Megan Parsons; Caroline Penal; Soheila Girakhoo; Svetlana O Pougatcheva; Juan Arroyo; Dennis W Trent; Thomas P Monath
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

2.  [Aedes albopictus (S) in the region of São José do Rio Preto, SP, Brazil: a study of its infestation in an area where Aedes aegypti was already established and a discussion of its role as a possible vector of dengue and yellow fever].

Authors:  Francisco Chiaravalloti-Neto; Margareth Regina Dibo; Angelita Anália Carniel Barbosa; Marcos Battigaglia
Journal:  Rev Soc Bras Med Trop       Date:  2002 Jul-Aug       Impact factor: 1.581

3.  Jungle yellow fever in the central Amazon.

Authors:  M L Barros; G Boecken
Journal:  Lancet       Date:  1996-10-05       Impact factor: 79.321

4.  Genetic variation in yellow fever virus: duplication in the 3' noncoding region of strains from Africa.

Authors:  E Wang; S C Weaver; R E Shope; R B Tesh; D M Watts; A D Barrett
Journal:  Virology       Date:  1996-11-15       Impact factor: 3.616

5.  Hepatitis and death following vaccination with 17D-204 yellow fever vaccine.

Authors:  R C Chan; D J Penney; D Little; I W Carter; J A Roberts; W D Rawlinson
Journal:  Lancet       Date:  2001-07-14       Impact factor: 79.321

6.  Fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996-2001.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2001-08-03       Impact factor: 17.586

Review 7.  Yellow fever: an update.

Authors:  T P Monath
Journal:  Lancet Infect Dis       Date:  2001-08       Impact factor: 25.071

8.  Advanced age a risk factor for illness temporally associated with yellow fever vaccination.

Authors:  M Martin; L H Weld; T F Tsai; G T Mootrey; R T Chen; M Niu; M S Cetron
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

9.  Ontogeny of yellow fever 17D vaccine: RNA oligonucleotide fingerprint and monoclonal antibody analyses of vaccines produced world-wide.

Authors:  T P Monath; R M Kinney; J J Schlesinger; M W Brandriss; P Brès
Journal:  J Gen Virol       Date:  1983-03       Impact factor: 3.891

10.  Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection.

Authors:  Kitisak Kengsakul; Kriengkrai Sathirapongsasuti; Sompone Punyagupta
Journal:  J Med Assoc Thai       Date:  2002-01
View more
  12 in total

1.  Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine.

Authors:  Kathleen M Daddario-DiCaprio; Thomas W Geisbert; Joan B Geisbert; Ute Ströher; Lisa E Hensley; Allen Grolla; Elizabeth A Fritz; Friederike Feldmann; Heinz Feldmann; Steven M Jones
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 2.  The yellow fever 17D virus as a platform for new live attenuated vaccines.

Authors:  Myrna C Bonaldo; Patrícia C Sequeira; Ricardo Galler
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

3.  Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii.

Authors:  Cristina T Stoyanov; Silvia B Boscardin; Stephanie Deroubaix; Giovanna Barba-Spaeth; David Franco; Ruth S Nussenzweig; Michel Nussenzweig; Charles M Rice
Journal:  Vaccine       Date:  2010-05-06       Impact factor: 3.641

4.  Long-term changes of serum chemokine levels in vaccinated military personnel.

Authors:  Beda Brichacek; Christophe Vanpouille; Alexander J Trachtenberg; Tatiana Pushkarsky; Larisa Dubrovsky; Gregory Martin; Gary Simon; Michael Bukrinsky
Journal:  BMC Immunol       Date:  2006-09-11       Impact factor: 3.615

5.  Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model.

Authors:  Deng Tao; Giovanna Barba-Spaeth; Urvashi Rai; Victor Nussenzweig; Charles M Rice; Ruth S Nussenzweig
Journal:  J Exp Med       Date:  2005-01-17       Impact factor: 14.307

6.  Broadening the horizons for yellow fever: new uses for an old vaccine.

Authors:  Heather L Van Epps
Journal:  J Exp Med       Date:  2005-01-17       Impact factor: 14.307

7.  A DNA vaccine against yellow fever virus: development and evaluation.

Authors:  Milton Maciel; Fábia da Silva Pereira Cruz; Marli Tenório Cordeiro; Márcia Archer da Motta; Klécia Marília Soares de Melo Cassemiro; Rita de Cássia Carvalho Maia; Regina Célia Bressan Queiroz de Figueiredo; Ricardo Galler; Marcos da Silva Freire; Joseph Thomas August; Ernesto T A Marques; Rafael Dhalia
Journal:  PLoS Negl Trop Dis       Date:  2015-04-13

8.  Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi.

Authors:  Raquel Tayar Nogueira; Alanderson Rocha Nogueira; Mirian Claudia Souza Pereira; Maurício Martins Rodrigues; Patrícia Cristina da Costa Neves; Ricardo Galler; Myrna Cristina Bonaldo
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

9.  Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines.

Authors:  Roland Züst; Luisa Cervantes-Barragán; Thomas Kuri; Gjon Blakqori; Friedemann Weber; Burkhard Ludewig; Volker Thiel
Journal:  PLoS Pathog       Date:  2007-08-10       Impact factor: 6.823

10.  Yellow fever and Max Theiler: the only Nobel Prize for a virus vaccine.

Authors:  Erling Norrby
Journal:  J Exp Med       Date:  2007-11-26       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.